<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4328">
  <stage>Registered</stage>
  <submitdate>28/02/2014</submitdate>
  <approvaldate>28/02/2014</approvaldate>
  <nctid>NCT02081378</nctid>
  <trial_identification>
    <studytitle>A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL</studytitle>
    <scientifictitle>A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CABL001X2101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Myelogenous Leukemia</healthcondition>
    <healthcondition>Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABL001
Treatment: drugs - ABL001 + Nilotinib
Treatment: drugs - ABL001
Treatment: drugs - ABL001+imatinib
Treatment: drugs - ABL001+dasatinib

Experimental: ABL001 in CML patients - Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with CML

Experimental: ABL001+Nilotinib in CML patients - Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with Nilotinib in adult CML patients

Experimental: ABL001 in Ph+ ALL patients - Dose escalation study to estimate the MTD and/or RDE of ABL001 in adult patients with Ph positive ALL patients

Experimental: ABL001+Imatinib in CML patients - Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with imatinib in adult CML patients

Experimental: ABL001+dasatinib in CML patients - Dose escalation study to estimate the MTD and/or RDE of ABL001 in combination with dasatinib in adult CML patients


Treatment: drugs: ABL001
ABL001 will be administered orally in a dose escalation schedule.

Treatment: drugs: ABL001 + Nilotinib
ABL001 and Nilotinib will be administered orally in CML patients

Treatment: drugs: ABL001
ABL001 will be administered orally in Ph+ ALL patients

Treatment: drugs: ABL001+imatinib
ABL001 and imatinib will be administered orally in CML patients

Treatment: drugs: ABL001+dasatinib
ABL001+dasatinib will be administered orally in CML patients

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatment - Determine the MTD and/or RDE of ABL001 as single agent in CML and Ph+ ALL, and in combination with either nilotinib or imatinib or dasatinib in CML patients</outcome>
      <timepoint>First Cycle is 28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hematologic Response</outcome>
      <timepoint>At screening and first day of cycle 2 and 3 and every 12 weeks afterwards</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cytogenetic response</outcome>
      <timepoint>at screening or when a patient's BCR-ABL ratio has risen to &gt;1%</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BCR-ABL transcript level</outcome>
      <timepoint>At screening and first day of cycle 2 and 3 and every 12 weeks afterwards</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmin of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUCinf of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUClast of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUCtau of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>T1/2 of ABL001 as measured in plasma</outcome>
      <timepoint>Cycle 1 days 1,2,8,15,16 and 22. Cycle 2 days 1 and 2, and subsequent cycles at the begining of each cycle up to cycle 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>Collected from screening visit through post-treatment follow-up period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For CML patients either:

          -  a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated
             with at least two different tyrosine kinase inhibitors prior to study entry and are
             relapsed, refractory to or intolerant of TKIs as determined by investigators or

          -  b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease
             associated with the presence of the T315I "gatekeeper mutation" after at least one TKI
             are also eligible provided that no other effective therapy exists

        For ALL and CML-BP patients:

          -  Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and
             are relapsed or refractory to at least one prior TKI or intolerant of TKIs. TKI
             failure for Ph+ ALL and CML-BP patients is defined as at least the loss of Molecular
             Response (MR) 4.5 (BCR-ABL = 0.0032%)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Willingness and ability to comply with all study procedures

          -  Written informed consent obtained prior to any screening procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Wash-out period:

          -  Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon and
             toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives,
             whichever is shorter, before the first dose of study treatment

          -  Therapy with TKIs as single agent within 5 half-lives before the first dose of study
             treatment

          -  Unconjugated monoclonal antibody therapies within 28 days or 5 half-lives, whichever
             is shorter, before the first dose of study treatment

          -  For patients receiving ABL001 in combination with either nilotinib or imatinib or
             dasatinib, intolerance to nilotinib, imatinib or dasatinib, respectivelyRadiotherapy
             with a wide field of radiation within 4 weeks or radiotherapy with a limited field of
             radiation for palliation within 1 week of the first dose of study treatment.

          -  CNS irradiation for meningeal leukemia, except if radiotherapy occurred &gt; 3 months
             previously. At least four weeks must have elapsed since prophylactic CNS irradiation
             given as part of a front-line therapy regimen for ALL

          -  Major surgery within 2 weeks before the first dose of study treatment

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Health Services Research</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>25/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>23/08/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Cedex 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The design of a phase I, open label, dose finding study was chosen in order to establish a
      safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed
      or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and
      ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02081378</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address />
      <phone>1-888-669-6682</phone>
      <fax />
      <email>Novartis.email@novartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>